EUCTR2021-005229-26-ES进行中（未招募）1 期
A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV)Viral Infectivity and Transmission in HPV16/18-Positive Women Before and After Vaccinationwith 9vHPV, a Multivalent L1 Virus-like Particle Vaccine, Evaluated in Cervical, Anal and OralSamples Obtained After One, Two, and Three Vaccine Doses (RIFT-HPV1/RIFT-HPV2). - RIFT-HPV
Dr. Miguel Angel Pavón Ribas0 个研究点目标入组 69 人开始时间: 2021年12月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •-Are women, aged 35 or 27 years or older for cohort 1 and cohort 2 respectively, attending a routine cervical cancer screening visit or gynaecological visit, are positive for HPV16, 18 or double-positive for 16 and 18 and negative for the rest of high-risk HPV types in a cervical sample, have been recently
- •diagnosed for their HPV-positivity (within the last 24 months) and meet one of the following criteria:
- •- have no apparent cervical lesion (cohort 1).
- •- have a CIN1/2 lesion which is eligible for conservative treatment (cohort 1).
- •- have multiple cervical, vulvar and/or anal lesions, and cervical lesions are eligible for conservative treatment (cohort 2).
- •-Are judged to have no major health conditions (based on medical history, physical examination, and laboratory testing) that may compromise their capacity to comply with study procedures.
- •-Provide written informed consent for their participation in the study.
- •-Provide a frequent contact telephone number as well as an alternate means of contact (such as an alternate telephone number or email) for follow-up purposes.
- •-Are planning to stay in their area of residence (near the study site) for the full duration of the study, so it is convenient for them to attend study visits at the site.
- •The following conditions ARE NOT CONSIDERED EXCLUSION CRITERIA. Therefore, candidates complying with them ARE ELIGIBLE FOR INCLUSION in the study:
- •-History of cervical surgery.
- •-History of condyloma acuminata.
- •-History of HIV or other immunosuppressive conditions, either acquired or medically induced.
- •-History of transplant immunosuppression.
- •-History of an autoimmune disease.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 69
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Medical Conditions
- •-Have any cervical lesion that requires clinical intervention within 7 months that could significantly affect cervical epithelia (and therefore, HPV viral production), such as cervical conization.
- •-Have a fever (defined as temperature =37.8°C) within the 24-hour period prior to the Day 1 visit*.
- •-Have a history of severe allergic reaction (e.g., swelling of the mouth and throat, difficultybreathing, hypotension, or shock) that required medical intervention.
- •-Are allergic to any vaccine component, including aluminium, yeast, or BENZONASETM (nuclease, Nicomedia [used to remove residual nucleic acids from this and other vaccines]). For this exclusion criterion, an allergy to vaccine components is defined as anallergic reaction that met the criteria for severe adverse event (SAE), defined as any
- •untoward medical occurrence that results in death, is life-threatening, requires hospitalization or results in persistent or significant disability/incapacity.
- •-Have known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection of study vaccine.
- •-Have a history of splenectomy.
- •-Have a history of ano-genital cancer or HPV-related head and neck cancer.
- •-Have a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study or interfere with the subject’s compliance of study procedures for the full duration of the study, such that their inclusion
- •in the study is not in the best interest of the subject and/or may compromise fulfilment of study’s objectives, by judgement of the investigator.
- •-Are, at the time of signing informed consent, using recreational or illicit drugs or have had a recent history (within the last year) of drug or alcohol abuse or dependence at the discretion of the investigator that might interfere with her capacity to comply with study
- •procedures. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems because of alcohol use.
- •-Are pregnant at the time of signing informed consent, are planning to be within the full duration of the study or become pregnant during the study period.
- •*For items denoted with an asterisk, if the exclusion criterion is met, then the Day 1 visit may
- •be rescheduled for a time when the criterion is not met.
- •Prior/Concomitant Therapy
- •-Have previously received any HPV vaccine.
- •-Have received within the 3 months prior to the Day 1 vaccination, are receiving, or plan to receive during Day 1 through Month 7 of the study, any immune globulin product (including RhoGAM™ [Ortho-Clinical Diagnostics]) or blood-derived product other than IVIG.
- •-Have received inactivated or recombinant vaccines within 14 days prior to Day 1 vaccination, or live vaccines within 21 days prior to Day 1 vaccination*.
- •Prior/Concurrent Clinical Study Experience
- •-Are concurrently enrolled in other clinical studies of investigational agents.
- •Sexual Activity
- •-Have engaged in sexual activity 48 hours prior to Day 1 (this may result in the detection of viral DNA that has been deposited in the oral cavity and is not the result of ongoing infection) * Sexual activity is defined as:
- •- Penile penetrative vaginal intercourse.
- •- Penile penetrative anal intercourse.
- •- Oral sex involving any contact between subject’s mouth with a partner’s genital or anal area.
- •*: For items denoted with an asterisk, if the exclusion criterion is met, then the Day 1 visit may be reschedu
研究者
相似试验
招募中
1 期
A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination.Evaluation of the reduction of HPV infectivity and transmission before and after vaccination with 9vHPVMedDRA version: 20.1Level: LLTClassification code: 10063001Term: Human papilloma virus infection Class: 10021881CTIS2024-515228-36-00Bellvitge University Hospital69
进行中（未招募）
不适用
A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A (FVIII:C <1%)Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 9.1Level: LLTClassification code 10018937Term: Haemophilia AEUCTR2008-008435-29-CZWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50
进行中（未招募）
1 期
A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A (FVIII:C <1%). - NDSevere hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 9.1Level: LLTClassification code 10018937EUCTR2008-008435-29-ITWyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research & Development50
进行中（未招募）
1 期
The main purpose of this study is to gather information regarding the safety of ReFacto AF, and how well it works (effectiveness) in children with severe Hemophilia A under the age of 12. Approximately 50 subjects, will take part in this study. 25 subjects will be 0-6 years of age and 25 subjects will be 6 to 12 years of age.Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 14.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2008-008435-29-FRWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50
进行中（未招募）
1 期
The main purpose of this study is to gather information regarding the safety of ReFacto AF, and how well it works (effectiveness) in children with severe Hemophilia A under the age of 12. Approximately 50 subjects, will take part in this study. 25 subjects will be 0-6 years of age and 25 subjects will be 6 to 12 years of age.Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 17.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850EUCTR2008-008435-29-BGWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50